drugset / Trial / NCT06321484
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
The goal of this research study is to evaluate the safety and effectiveness of the use of cytokine-induced memory-like (CIML) natural killer (NK) cell therapy in recurrent, high grade ovarian cancer (HGOC). Names of the study therapies involved in this study are: CIML NK (cellular therapy) Interleukin-2 (IL-2)
Timeline
- Start
- 2024-10-09
- Primary completion
- 2026-11-30
- Completion
- 2031-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CIML-NK Cells | Cell therapy | — | Other |
| Background | aldesleukin | Protein / enzyme biologic | — | Subcutaneous |